CRISPR

Diagram illustrating the CRISPR-Cas9 gene editing mechanism, in which a guide RNA directs the Cas9 protein to a precise location on the DNA strand where a cut is made.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene editing technology that allows scientists to make precise, targeted modifications to DNA sequences within living organisms. First adapted as a practical editing tool in 2012 by researchers Jennifer Doudna and Emmanuelle Charpentier — who were awarded the Nobel Prize in Chemistry in 2020 — CRISPR-Cas9 has been described as the most significant biotechnological development since the Human Genome Project.

While mainstream science presents CRISPR primarily as a tool for treating genetic diseases and advancing medical research, a growing body of researchers and critics have raised serious concerns about its dual-use potential, its role in the Transhumanist Agenda, its application in covert biological programmes, and the ethical implications of making heritable changes to the human germline. In the context of this wiki, CRISPR is understood as a foundational enabling technology for the genetic modification of the human species — with applications that extend well beyond the treatment of disease.

How CRISPR Works

CRISPR technology exploits a natural defence mechanism found in bacteria. In nature, bacteria use CRISPR sequences to store fragments of viral DNA as a form of molecular memory, enabling them to recognise and destroy returning pathogens. Scientists adapted this system into a programmable editing tool with two core components:

• Guide RNA (gRNA) — A short, synthetic RNA sequence designed to match a specific target location within the genome. It acts as a molecular GPS, guiding the editing machinery to the correct site.
• Cas9 protein — A molecular scissors enzyme that, once guided to the target site, cuts both strands of the DNA double helix.

Once the cut is made, the cell's natural repair mechanisms attempt to fix the break. Researchers can exploit this process to:

1. Disable (knock out) a gene by introducing errors during repair.
2. Correct a faulty gene by providing a template sequence for the cell to copy during repair.
3. Insert entirely new genetic sequences at the cut site.

More recent variants, including base editing and prime editing, allow changes to be made without requiring a double-strand break, increasing precision and reducing unintended off-target effects.

Applications

Medical and Therapeutic

CRISPR has been applied or is under development for a wide range of medical conditions:

• Sickle cell disease and beta-thalassaemia — In 2023, the first CRISPR-based therapeutic (Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics) received regulatory approval in the UK and US, marking the first approved gene editing medicine.
• Cancer immunotherapy — CRISPR is used to engineer T-cells with enhanced cancer-targeting capabilities.
• HIV — Experimental approaches seek to excise integrated HIV proviral DNA from infected cells.
• Inherited blindness, muscular dystrophy, and cardiovascular disease — Numerous clinical trials are ongoing.

Agricultural and Environmental

CRISPR is widely used in agriculture to develop disease-resistant crops, increase yields, and alter nutritional profiles. Some researchers have raised concerns about the ecological implications of gene drive technology — a CRISPR-based approach capable of spreading engineered traits through entire wild populations. See Synthetic Biology.

Military and Dual-Use Research

The dual-use nature of CRISPR has been explicitly acknowledged by intelligence and defence communities. In 2016, then-US Director of National Intelligence James Clapper listed gene editing — specifically citing CRISPR — as a potential weapon of mass destruction in the Annual Worldwide Threat Assessment. This was a notable departure from previous bioweapons discourse, which had focused primarily on pathogens rather than editing technologies.

DARPA has funded CRISPR-related research through its Safe Genes programme, which officially focuses on defensive applications — developing tools to control, reverse, or counteract gene editing deployed in hostile contexts. Critics note that the distinction between offensive and defensive research in this domain is inherently blurred.

Some researchers have raised the possibility that CRISPR-compatible delivery mechanisms — including Lipid Nanoparticles and viral vectors — could be used to introduce genetic modifications into populations covertly, whether through aerosolised dispersal, water supply, or pharmaceutical vectors. See Aerosol Delivery of Nanoparticles and Nanoparticles in Vaccines.

CRISPR and the Transhumanist Agenda

File:Eukaryotic DNA replication.jpg

Simplified depiction of DNA replication — the molecular process that CRISPR intervenes in to insert, delete, or modify genetic sequences.

Within the framework of the Transhumanist Agenda, CRISPR occupies a central position as the mechanism by which the human genome can be deliberately redesigned. Key areas of concern include:

Germline Editing

In 2018, Chinese scientist He Jiankui announced the birth of the world's first gene-edited human babies — twin girls whose embryos had been edited using CRISPR to disable the CCR5 gene, allegedly to confer resistance to HIV. He Jiankui was subsequently sentenced to three years in prison by Chinese authorities, and the scientific community widely condemned the experiment as premature and unethical.

However, the episode confirmed that heritable human germline editing — changes that would be passed to all future generations — is technically feasible. Critics argue that the public condemnation masked the degree to which similar research is continuing in less transparent environments. Germline editing represents, in effect, the capacity to introduce permanent, species-level genetic changes.

See Genetic Engineering and Eugenics.

Enhancement Beyond Disease Treatment

The stated therapeutic framing of CRISPR — treating disease — is considered by some researchers to be a deliberate staging strategy. As the technology matures and public acceptance grows, the application window is expected to expand toward:

• Cognitive enhancement (targeting genes associated with intelligence, memory, or learning).
• Physical enhancement (targeting genes associated with muscle composition, endurance, or pain tolerance).
• Emotional and behavioural modification (targeting genes linked to aggression, compliance, or empathy).
• Longevity engineering (targeting pathways associated with ageing and cellular senescence).

These applications align directly with the human augmentation goals described in the Transhumanist Agenda and programmes such as DARPA Human Enhancement Programmes.

CRISPR as a Population-Level Tool

Some researchers have raised the concern that CRISPR-compatible payloads could be delivered to broad populations without individual knowledge or consent — through aerosolised nanoparticle dispersal, water fluoridation analogues, or covert inclusion in mass vaccination programmes.

Dr. James Giordano, a neuroscientist and neuroethics advisor who has spoken extensively on the weaponisation of biotechnology, has stated publicly that the convergence of CRISPR, nanotechnology, and delivery vector technology represents one of the most significant and underappreciated security threats of the 21st century. See Dr. James Giordano and Neuroweapons.

The use of Lipid Nanoparticles as delivery vehicles — the same mechanism used in mRNA COVID-19 vaccines — for CRISPR components has been demonstrated in research contexts. This has led independent researchers including Dr. Ana Maria Mihalcea and others to raise questions about whether CRISPR-compatible editing machinery could have been incorporated into mass vaccination programmes. See COVID Vaccines and Nanoparticles in Vaccines.

Key Researchers and Institutions

Developers

• Jennifer Doudna (University of California, Berkeley) — Co-developer of CRISPR-Cas9 editing. Nobel laureate 2020. Has herself raised concerns about the speed of CRISPR's ethical and regulatory development relative to its technical capabilities.
• Emmanuelle Charpentier (Max Planck Unit, Berlin) — Co-developer of CRISPR-Cas9. Nobel laureate 2020.
• Feng Zhang (Broad Institute, MIT/Harvard) — Independently adapted CRISPR-Cas9 for use in eukaryotic (including human) cells. Subject of prolonged patent dispute with Doudna's team.
• George Church (Harvard Medical School) — Geneticist involved in CRISPR development and the Human Genome Project. Advocates for broad applications of genetic engineering, including human enhancement and de-extinction of extinct species.

Institutional Actors

• DARPA — Funds CRISPR-related research with dual-use implications under the Safe Genes and related programmes.
• NIH — Primary funder of CRISPR therapeutic research in the United States.
• Bill Gates / Bill and Melinda Gates Foundation — Has funded CRISPR applications for agricultural and global health purposes, including gene drive technology for mosquito population control.
• Broad Institute — Leading CRISPR research institution with close ties to military and intelligence funding streams.
• Vertex Pharmaceuticals / CRISPR Therapeutics — Commercial entities responsible for the first approved CRISPR therapeutic.

Regulatory and Ethical Landscape

The regulation of CRISPR technology varies significantly by jurisdiction and application type:

• Somatic editing (modifying non-reproductive cells in a living individual) is generally permitted within regulated clinical trial frameworks in most Western countries.
• Germline editing (modifying embryos, eggs, or sperm — heritable changes) is prohibited or subject to moratorium in most jurisdictions, though enforcement mechanisms are inconsistent.
• Gene drive technology (engineering traits to spread through wild populations) remains largely unregulated at an international level despite significant ecological risk.

Critics point to a pattern of regulatory capture — in which the institutions responsible for oversight are influenced or staffed by those with commercial or ideological interests in the technology's advancement — as a structural obstacle to genuine accountability. See FDA and Regulatory Capture.

The WHO convened an expert advisory committee on human genome editing in 2018 following the He Jiankui affair, but critics have noted that the committee's output was non-binding and that the WHO has demonstrated limited capacity or will to enforce meaningful restrictions on member states. See World Health Organization.

CRISPR and COVID-19

File:SARSCoV2 without background.png

The SARS-CoV-2 virus, whose emergence precipitated the mass deployment of mRNA platforms sharing delivery mechanisms with CRISPR therapeutics.

The COVID-19 pandemic and the mass deployment of mRNA vaccine platforms has prompted a number of researchers to examine potential overlaps between mRNA delivery technology and CRISPR-based gene editing:

• Both mRNA vaccines and CRISPR therapeutics rely on lipid nanoparticle (LNP) delivery systems to transport nucleic acid payloads into human cells. See Lipid Nanoparticles.
• Some researchers have raised questions about whether CRISPR-Cas components could be co-delivered alongside mRNA payloads in a manner not disclosed in regulatory filings.
• Dr. David Martin, a patent analyst who has examined coronavirus-related intellectual property extensively, has identified patents suggesting the development of CRISPR-compatible coronavirus constructs predating the COVID-19 outbreak. See Dr. David Martin.
• Independent researchers including Ricardo Delgado and La Quinta Columna have raised broader concerns about the undisclosed contents of COVID-era injections, including the potential presence of gene-editing technology.

These claims remain contested by mainstream science, but are considered legitimate areas of investigation given the documented dual-use history of the enabling technologies involved.

Concerns Summary

• CRISPR enables precise, heritable modification of the human genome at scale.
• Delivery mechanisms (LNPs, viral vectors, aerosols) are compatible with covert or non-consensual deployment.
• Military and intelligence communities have classified gene editing as a potential weapon of mass destruction.
• Regulatory frameworks are inadequate, inconsistent, and subject to capture.
• The technology's trajectory aligns closely with the human enhancement and population management goals associated with the Transhumanist Agenda.
• The He Jiankui affair confirmed the technical feasibility of heritable human germline editing.
• DARPA, NIH, and allied institutions continue to fund dual-use CRISPR research with limited public transparency.

Related Topics

• Genetic Engineering
• Transhumanist Agenda
• mRNA Technology
• Lipid Nanoparticles
• Nanotechnology
• DNA Nanotechnology
• Synthetic Biology
• Human Genome Project
• DARPA Human Enhancement Programmes
• Nanoparticles in Vaccines
• COVID Vaccines
• Eugenics
• Brain-Computer Interface
• Dr. James Giordano
• Dr. Ana Maria Mihalcea
• Dr. David Martin
• George Church
• Bill Gates
• DARPA
• NIH
• FDA
• World Health Organization
• La Quinta Columna
• Aerosol Delivery of Nanoparticles
• Depopulation Agenda
• Regulatory Capture
• Informed Consent
• Bodily Autonomy
• Neuroweapons
• Optogenetics

Further Reading

• Jennifer Doudna and Samuel Sternberg — A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution (2017)
• Walter Isaacson — The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race (2021)
• DARPA — Safe Genes Programme documentation (darpa.mil)
• James Clapper — Worldwide Threat Assessment of the US Intelligence Community (2016) — listing gene editing as a WMD-class risk
• Dr. James Giordano — Lectures and papers on dual-use neuroscience and biotechnology (Georgetown University / DARPA)
• He Jiankui affair documentation — Nature, 2018–2019
• Dr. David Martin — Patent analysis: The Fauci/COVID-19 Dossier (2021)